{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:57:59Z","timestamp":1784282279558,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":1315,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.7861\/clinmed.2020-0697","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T09:25:11Z","timestamp":1600161911000},"page":"513-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["An update on the management of cholestatic liver diseases"],"prefix":"10.1016","volume":"20","author":[{"given":"Gautham","family":"Appanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiannis","family":"Kallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.7861\/clinmed.2020-0697_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep4.1044","article-title":"Toward solving the etiological mystery of primary biliary cholangitis","volume":"1","author":"Tanakaa","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.7861\/clinmed.2020-0697_bib2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/hep.510300213","article-title":"Primary biliary cirrhosis once rare, now common in the United Kingdom","volume":"30","author":"James","year":"1999","journal-title":"Hepatology"},{"key":"10.7861\/clinmed.2020-0697_bib3","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.28140","article-title":"Changing nomenclature for PBC: From \u2018cirrhosis\u2019 to \u2018cholangitis\u2019","volume":"62","author":"Beuers","year":"2015","journal-title":"Hepatology"},{"key":"10.7861\/clinmed.2020-0697_bib4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.5009\/gnl16365","article-title":"Extrahepatic manifestations of primary biliary cholangitis","volume":"11","author":"Chalifoux","year":"2017","journal-title":"Gut Liver"},{"key":"10.7861\/clinmed.2020-0697_bib5","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMct074694","article-title":"Ursodeoxycholic acid for the treatment of primary biliary cirrhosis","volume":"357","author":"Lindor","year":"2007","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2020-0697_bib6","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2020-0697_bib7","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"29","author":"Poupon","year":"1999","journal-title":"Hepatology"},{"key":"10.7861\/clinmed.2020-0697_bib8","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"10.7861\/clinmed.2020-0697_bib9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.7861\/clinmed.2020-0697_bib10","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2020-0697_bib11","doi-asserted-by":"crossref","first-page":"e7116","DOI":"10.1097\/MD.0000000000007116","article-title":"Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom","volume":"96","author":"Liang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.7861\/clinmed.2020-0697_bib12","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"10.7861\/clinmed.2020-0697_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol"},{"key":"10.7861\/clinmed.2020-0697_bib14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.7861\/clinmed.2020-0697_bib15","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.7861\/clinmed.2020-0697_bib16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/apt.15375","article-title":"Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis","volume":"50","author":"R\u00fchlemann","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.7861\/clinmed.2020-0697_bib17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.7861\/clinmed.2020-0697_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.7861\/clinmed.2020-0697_bib19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis \u2013 a pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.7861\/clinmed.2020-0697_bib20","article-title":"Clinical impact of digital cholangioscopy in management of indeterminate biliary strictures and complex biliary stones: a single-center study","volume":"12","author":"Yan","year":"2019","journal-title":"Ther Adv Gastrointest Endosc"},{"key":"10.7861\/clinmed.2020-0697_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11901-020-00514-0","article-title":"The role of cholangioscopy in the management of primary sclerosing cholangitis","volume":"19","author":"Montano-Loza","year":"2020","journal-title":"Curr Hepatol Reports"},{"key":"10.7861\/clinmed.2020-0697_bib22","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMra1506330","article-title":"Primary sclerosing cholangitis","volume":"375","author":"Lazaridis","year":"2016","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmed.2020-0697_bib23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3748\/wjg.v25.i6.659","article-title":"Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies","volume":"25","author":"Fung","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.7861\/clinmed.2020-0697_bib24","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.24570","article-title":"Cancer surveillance in patients with primary sclerosing cholangitis","volume":"54","author":"Razumilava","year":"2011","journal-title":"Hepatology"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824034791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824034791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmed.2020-0697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:39:41Z","timestamp":1761460781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824034791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1470211824034791"],"URL":"https:\/\/doi.org\/10.7861\/clinmed.2020-0697","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on the management of cholestatic liver diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmed.2020-0697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2020. All rights reserved.","name":"copyright","label":"Copyright"}]}}